Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly's blockbuster diabetes drug Mounjaro demonstrated significant cardiovascular and all-cause mortality benefits in a late-stage trial directly comparing it to the company's older treatment, Trulicity, showing an 8% reduction in cardiovascular events and a 16% lower all-cause death rate. While Lilly views these results as strengthening Mounjaro's market position and potential as a first-line choice, particularly ahead of Trulicity's 2027 patent expiration, shares fell nearly 2% as the data did not meet some analysts' superiority benchmarks. Despite the robust clinical findings, Mounjaro's higher list price and existing broad coverage for Type 2 diabetes patients may temper immediate significant expansion of use, though the data solidifies Lilly's competitive lead in the cardiometabolic drug market.

Analysis

Eli Lilly's late-stage trial directly comparing Mounjaro to its older drug, Trulicity, yielded clinically positive but commercially nuanced results. While Mounjaro met its primary endpoint of non-inferiority for major adverse cardiovascular events (MACE), the 8% risk reduction did not meet some analyst benchmarks for clear superiority, contributing to a nearly 2% premarket share decline. However, the study revealed more profound secondary benefits, including a 16% lower rate of all-cause mortality and greater kidney protection, which clinicians described as "clinically meaningful." This data strategically positions Mounjaro as the definitive successor to Trulicity, which faces a patent cliff in 2027, and strengthens Eli Lilly's competitive standing against Novo Nordisk in the broader cardiometabolic market. The primary challenge remains market access and pricing; despite Lilly's assertion that the results make it "harder to say no to covering this medicine," some experts suggest insurers may balk at Mounjaro's higher list price without a more substantial MACE benefit over the incumbent drug. The company's plan to submit the data to global regulators by year-end for a potential 2026 approval for this specific indication is a key step toward securing broader insurance coverage.

Key Decisions for Investors

• Investors should view these results as reinforcing the long-term bullish thesis for Eli Lilly, as the compelling all-cause mortality reduction solidifies Mounjaro's clinical profile and its role as the heir to Trulicity ahead of its 2027 patent expiration.
• Monitor payer negotiations and insurance formulary decisions closely, as the lack of a clear superiority finding on the primary cardiovascular endpoint, combined with a higher price, could create near-term headwinds for Mounjaro's adoption rate and reimbursement status.
• The data provides a negative competitive read-through for Novo Nordisk, and portfolio managers should consider underweighting NVO relative to LLY to reflect Eli Lilly's strengthening competitive moat in the lucrative GLP-1 drug class.
• The planned regulatory submission by year-end and potential 2026 approval for the expanded cardiovascular indication are key upcoming catalysts that could significantly de-risk the commercial outlook and should be tracked for entry or position-sizing adjustments.